Please ensure Javascript is enabled for purposes of website accessibility

$50,000 Per Year in Prescription Drugs? You Likely Know Someone Who Used at Least That Much

By Keith Speights – Updated Oct 10, 2017 at 4:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Only one-third of 1% of Americans had such high prescription costs last year, but they account for more than a fifth of the spending in the category.

For most Americans, $50,000 is a lot of money. Six out of 10 households in the U.S. make less than that amount per year (based on adjusted gross income). But, for a growing number of Americans, that's how much -- or more -- was spent on their prescription medications last year.

Leading pharmacy benefits manager (PBM) Express Scripts (ESRX) recently released its 2016 Drug Trend Report. The company found that 870,000 Americans had prescription medication costs of at least $50,000 last year -- up 35% from just two years ago. Statistically speaking, it's pretty likely that you personally know some of these people. But despite these staggering numbers, there's actually some good news. 

Pills and pill bottles with money in one of the bottles

Image source: Getty Images.

Big costs, small number of patients

Express Scripts' research found that less than one-third of 1% of the U.S. population accounted for 21.3% of total pharmacy costs in 2016 -- about $80 billion. Around two out of every million Americans generated prescription spending of $1 million or more last year.

Despite these really low numbers of individuals with really big prescription drug costs, Express Scripts executive Glen Stettin stated that most Americans probably know someone in this category. Stettin said that pretty much everyone in the U.S. is "on a first-name basis with at least one other person -- a relative, friend, or colleague -- who has annual drug costs that are nearly the same amount as the median U.S. household income."

Nearly half of those with annual prescription spending of $50,000 or more were Baby Boomers (ages 53 to 71). One quarter, though, were between the ages of 34 and 52.

What about the rest of the U.S. population? Nearly one-third (32%) had no prescription drug costs at all in 2016, and for almost 83%, the costs were less than $1,000. What we're seeing appears to be a tightened-down version of the Pareto principle, which observes that in many situations, around 80% of outcomes are driven by 20% of causes.

What's costing so much?

In 2014, the two biggest drivers of super-high prescription drug spending were compounded medications and hepatitis C drugs. It's a much different story today. Express Scripts reported that spending on compounded medications "virtually disappeared" from the prescription lists of patients with high spending levels due to the emergence of safer and lower-cost alternatives.

As for hepatitis C drugs, their costs dropped by 34% in 2016. Gilead Sciences (GILD 0.98%) led this change with its launch of Sovaldi in late 2013. Sovaldi cured most hepatitis C patients. The big biotech followed up with more powerful treatments, as did other drugmakers. As a result, the numbers of hepatitis C patients has declined markedly. Express Scripts found that utilization of hepatitis C treatments plunged more than 27% last year -- the biggest factor behind the disease being a much less significant factor in high prescription drug spending.

So what is driving prescription drug costs now? Three therapeutic categories account for more than 55% of total spending for patients with annual costs of $50,000 or more. At the top of the list is cancer, generating nearly 26% of total prescription spending. Overall oncology drug spending grew by 21.5% last year. Three drugs led the way: Celgene's (CELG) Revlimid, and two chemotherapies -- capecitibine and Novartis' (NVS 0.48%) Gleevec.

Cancer pills on top of document with end of stethoscope and hand holding syringe

Image source: Getty Images.

The second major category was multiple sclerosis (MS), which generated 18.3% of spending for the $50,000-plus group. Coming in third was inflammatory conditions, such as rheumatoid arthritis and psoriasis, which accounted for 11.6% of spending for patients with $50,000 or more in annual drug costs. Among all patients, though, inflammatory conditions ranked as the largest single therapy class in total prescription drug spending. 

The good news

Fortunately for the patients, most of those high costs weren't borne directly by individuals themselves. Express Scripts reported that employers, insurers and government payers covered nearly 98% of total prescription drug costs. Among Americans whose prescription drug costs exceeded $50,000 last year, the average out-of-pocket cost was $2,156.

In other good news, some drugs' costs could be coming down. That's already happened in hepatitis C, with Gilead Sciences and others lowering prices. There are generic versions of Gleevec on the market, and the most-prescribed MS drug, Teva Pharmaceuticals' (TEVA 0.80%) Copaxone, also has generic alternatives. Naturally, that's not the case for all of the high-prices treatments. Celgene's Revlimid, for example, is projected to be the highest-grossing cancer drug in the world soon with sales of more than $14 billion by 2022.

Perhaps most importantly, much of the spending driving the higher costs is for treatments addressing rare and serious diseases for which there aren't many treatment options. Although $50,000 is definitely a lot of money, most of the patients whose lives are improved as a result of these drugs probably consider it money well spent.

Keith Speights owns shares of Celgene, Express Scripts, and Gilead Sciences. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool owns shares of Express Scripts and has the following options: short October 2017 $86 calls on Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Express Scripts Holding Company Stock Quote
Express Scripts Holding Company
ESRX
Teva Pharmaceutical Industries Stock Quote
Teva Pharmaceutical Industries
TEVA
$8.87 (0.80%) $0.07
Gilead Sciences Stock Quote
Gilead Sciences
GILD
$86.26 (0.98%) $0.84
Celgene Stock Quote
Celgene
CELG
Novartis Stock Quote
Novartis
NVS
$87.71 (0.48%) $0.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.